Max Robotics — Global Service Robot Directory + US Certification

About

Yi-Kai Chang is a leading urologic oncologist whose research focuses on improving risk stratification and treatment outcomes for prostate cancer. His work has been instrumental in refining the use of biomarkers and comparing therapeutic strategies for aggressive disease. Chang’s most impactful study (9 citations) validated the Prostate Health Index (PHI) and its derivative, %p2PSA, as superior predictors of adverse pathology in men undergoing radical prostatectomy, offering a non-invasive tool to guide surgical decisions. He also identified a critical paradox in high-grade, locally-advanced prostate cancer: patients with paradoxically low initial PSA levels face a greater risk of disease progression (8 citations), challenging conventional assumptions about tumor biology. In a major comparative effectiveness study (7 citations), Chang employed propensity score matching to demonstrate that robotic-assisted radical prostatectomy may offer survival advantages over radiotherapy with long-term androgen deprivation therapy for locally advanced disease. His work bridges the gap between biomarker discovery and clinical decision-making, directly impacting how clinicians identify high-risk patients and select optimal treatments. By integrating novel serum markers with rigorous surgical outcomes analysis, Chang continues to shape precision oncology for one of the most common male malignancies.